Cue Biopharma, Inc.
CUECue Biopharma, Inc. is a biotechnology company focused on developing immunotherapies that modulate the immune system by targeting specific T-cell pathways. Utilizing its proprietary drug discovery platform, Cue aims to create personalized treatments for cancer and other diseases by leveraging immune system modulation to enhance therapeutic outcomes.
Company News
The head and neck squamous cell carcinoma (HNSCC) market is expected to grow at a CAGR of 10.5% from 2026-2036, driven by rising cancer incidence, increased adoption of immunotherapies, and the launch of emerging novel treatments. The market was valued at USD 850 million in 2025 across seven major markets, with KEYTRUDA currently generating the h...
Cue Biopharma secured $50 million in funding through a private placement led by Cormorant Asset Management and Columbia Threadneedle Investments. The company will use proceeds to advance clinical development of its immunological disorder therapies, including Phase 2 data expected from a CSU study in China by Q3 2026.
Cue Biopharma granted inducement equity awards to seven new employees on May 3, 2026, including newly appointed President and CEO Shao-Lee Lin, M.D., Ph.D. Dr. Lin received stock options for 655,074 shares and 327,537 restricted stock units, while six other new employees received aggregate options for 518,599 shares and 327,534 RSUs, all at an ex...
Cue Biopharma announced it will receive a $7.5 million preclinical milestone payment from Boehringer Ingelheim following the selection and approval of the first compound for lead optimization under their collaboration agreement. The company is eligible for up to $337.5 million in additional milestone and royalty payments. Cue Biopharma continues ...
Despite regulatory challenges and budget cuts, the oncology market is projected to reach US$900 billion by 2034, with several biotech companies advancing innovative cancer therapies and demonstrating promising clinical trial results.
